The AI-HAND consortium convened on February 18-19, 2026 at the Centre National de Rééducation Fonctionnelle et de Réadaptation (Rehazenter) in Luxembourg, marking a pivotal moment in the advancement of neuroprosthetic technology. The meeting brought together clinicians, engineers, neuroscientists, researchers, and rehabilitation specialists from across Europe to review progress, tackle challenges, and chart the course for the project’s next phase.
Highlights from the meeting
Discussions at the meeting centered on the upcoming steps – regulatory, clinical and technological – to prepare for the First-In-Human (FIH) clinical trial, a critical milestone for translating research into real-world applications. Promising results and early findings from animal studies and non-invasive trials were presented, offering valuable insights to refine selective neural stimulation techniques. Discussions fostered the technological development of the Active Implantable Medical Device (AIMD), by focusing on enhancing the automatic control of the neuroprosthesis and biomechanically evaluating movements triggered by electrical stimulation.
A Collaborative Force
The interdisciplinary nature of the consortium, characterised by open dialogue and a shared commitment to innovation, was highlighted as a driving force behind the project’s success. Participants expressed enthusiasm for the strong European collaboration, emphasising the collective effort to push the boundaries of neuroprosthetic technology.
“It’s incredibly motivating to be part of such a dedicated team,” remarked the project scientific coordinator. “The progress we’ve made so far is a testament to what we can achieve when experts from diverse fields come together with a common goal.
